Kezar’s Lead Asset Bounces Back With Lupus Win
Following Myositis Setback
Executive Summary
Kezar’s lead asset zetomipzomib has demonstrated clinical significance in a mid-stage lupus trial just weeks after a disappointment in myositis but more robust data are needed for the first-in-class selective immunoproteasome inhibitor.
You may also be interested in...
GSK Makes ADC Pipeline Comeback With Mersana Deal
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger
The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.
AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.